PRQR:NASDAQProQR Therapeutics N.V. Analysis
Data as of 2026-08-26 - not real-time
$2.38
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind ProQR Therapeutics N.V. is bullish at $2.38, with short-term averages leading the long-term ones. Over a rolling month the price has gained 40.0%. Relative strength is 71.9 — overbought — and the MACD signal is bullish. The recent range runs from support at $1.68 up to resistance at $2.46.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 245.5% above where the shares trade now. Revenue is growing at 120.4% on a -228.2% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 64.3%, a beta of 1.66 and a maximum drawdown of 55.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 1/10 conviction over the longer horizon.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 245.5% above where the shares trade now. Revenue is growing at 120.4% on a -228.2% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 64.3%, a beta of 1.66 and a maximum drawdown of 55.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 1/10 conviction over the longer horizon.
Top Market Events
4dProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other CatalystsAxiomer RNA editing shows strong phase 1...
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- RSI at 71.9 signals overbought conditions
- Trading above the 200-day average of 1.78
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked above long-term ones
- RSI at 71.9 signals overbought conditions
- Trading above the 200-day average of 1.78
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Negative profit margin of -228.2%
- Analyst targets imply +245.5% versus the current price
- Negative return on equity of -57.4%
Key Metrics & Analysis
Financial Health
Revenue Growth120.40%
Profit Margin-228.18%
P/E Ratio-5.0
ROE-57.40%
ROA-19.76%
Debt/Equity19.27
P/B Ratio2.8
Op. Cash Flow$-49007000
Free Cash Flow$-19073124
Industry P/E31.2
Technical Analysis
TrendBullish
RSI71.9
Support$1.68
Resistance$2.46
MA 20$1.98
MA 50$1.83
MA 200$1.78
MACDBullish
VolumeIncreasing
Fear & Greed Index93.84
Valuation
Target Price$8.22
Upside/Downside245.47%
GradeFair
TypeGrowth
Risk Assessment
Beta1.66
Volatility64.28%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.